Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Ur2lurking

I believe I read that the USPTO will defer to the courts as well. If a trial was to start today there would be plenty of time to finish these reexaminations but they need to be based on the claims of the patent which are changing.

By the time the trial ends our patents should read:

Reexamination Denied

Reexamination Denied

Reexamination Denied

Reexamination Denied

Reexamination Denied

Share
New Message
Please login to post a reply